CSPC Pharmaceutical Group Limited

OTCPK:CHJT.F Stock Report

Market Cap: US$7.6b

CSPC Pharmaceutical Group Valuation

Is CHJT.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CHJT.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CHJT.F ($0.67) is trading below our estimate of fair value ($1.25)

Significantly Below Fair Value: CHJT.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CHJT.F?

Key metric: As CHJT.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CHJT.F. This is calculated by dividing CHJT.F's market cap by their current earnings.
What is CHJT.F's PE Ratio?
PE Ratio10.7x
EarningsCN¥5.16b
Market CapCN¥55.19b

Price to Earnings Ratio vs Peers

How does CHJT.F's PE Ratio compare to its peers?

The above table shows the PE ratio for CHJT.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28x
JAZZ Jazz Pharmaceuticals
16.5x16.3%US$7.6b
ELAN Elanco Animal Health
32.2x2.7%US$6.6b
CORT Corcept Therapeutics
42.9x41.0%US$5.9b
PBH Prestige Consumer Healthcare
20.4x5.4%US$4.2b
CHJT.F CSPC Pharmaceutical Group
10.7x2.7%US$59.3b

Price-To-Earnings vs Peers: CHJT.F is good value based on its Price-To-Earnings Ratio (10.7x) compared to the peer average (28x).

Price to Earnings Ratio vs Industry

How does CHJT.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

9 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.6xn/aUS$1.87b
PROC Procaps Group
2xn/aUS$125.23m
KPRX Kiora Pharmaceuticals
1.8x-40.4%US$9.93m
EDXC Endexx
0.8xn/aUS$5.99m
CHJT.F 10.7xIndustry Avg. 19.3xNo. of Companies9PE01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CHJT.F is good value based on its Price-To-Earnings Ratio (10.7x) compared to the US Pharmaceuticals industry average (19.3x).

Price to Earnings Ratio vs Fair Ratio

What is CHJT.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CHJT.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CHJT.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CHJT.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.67
US$0.94
+40.9%
29.1%US$1.66US$0.60n/a27
Nov ’25n/a
US$1.02
0%
26.0%US$1.66US$0.64n/a27
Oct ’25n/a
US$1.03
0%
23.7%US$1.66US$0.55n/a27
Sep ’25US$0.62
US$1.03
+66.4%
22.8%US$1.65US$0.62n/a27
Aug ’25n/a
US$1.22
0%
18.2%US$1.66US$0.76n/a27
Jul ’25n/a
US$1.23
0%
17.5%US$1.66US$0.83n/a28
Jun ’25n/a
US$1.23
0%
17.5%US$1.66US$0.83n/a28
May ’25n/a
US$1.19
0%
18.5%US$1.66US$0.75n/a28
Apr ’25n/a
US$1.19
0%
18.9%US$1.66US$0.75n/a27
Mar ’25US$0.81
US$1.20
+49.1%
18.7%US$1.66US$0.75n/a26
Feb ’25n/a
US$1.21
0%
17.8%US$1.66US$0.83n/a26
Jan ’25n/a
US$1.22
0%
17.4%US$1.66US$0.83n/a26
Dec ’24US$0.89
US$1.22
+37.4%
17.5%US$1.66US$0.83n/a25
Nov ’24n/a
US$1.21
0%
19.8%US$1.66US$0.69n/a25
Oct ’24n/a
US$1.31
0%
24.1%US$2.20US$0.69n/a29
Sep ’24US$0.77
US$1.32
+71.6%
22.9%US$2.19US$0.69US$0.6230
Aug ’24n/a
US$1.42
0%
18.9%US$2.21US$0.79n/a30
Jul ’24n/a
US$1.42
0%
18.6%US$2.20US$0.79n/a30
Jun ’24US$0.83
US$1.43
+71.5%
18.5%US$2.20US$0.79n/a30
May ’24n/a
US$1.50
0%
14.1%US$2.19US$1.02n/a29
Apr ’24US$0.99
US$1.50
+51.6%
14.3%US$2.19US$1.02n/a28
Mar ’24n/a
US$1.58
0%
13.0%US$2.19US$1.02US$0.8129
Feb ’24n/a
US$1.58
0%
13.1%US$2.20US$1.02n/a29
Jan ’24US$1.01
US$1.58
+56.4%
12.8%US$2.20US$1.02n/a30
Dec ’23n/a
US$1.58
0%
12.8%US$2.20US$1.02US$0.8930
Nov ’23n/a
US$1.53
0%
14.7%US$2.19US$1.02n/a26

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Kiniksa Pharmaceuticals International

US$1.5b

A biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.

KNSA

US$21.28

7D

-0.05%

1Y

33.2%

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$17.12

7D

4.2%

1Y

79.3%